Dopamine D 4 receptor stimulation prevents nigrostriatal dopamine pathway activation by morphine: relevance for drug addiction

• Published in: Addiction biology Vol. 22; no. 5; p. 1232
• Main Authors: Rivera, Alicia, Gago, Belén, Suárez-Boomgaard, Diana, Yoshitake, Takashi, Roales-Buján, Ruth, Valderrama-Carvajal, Alejandra, Bilbao, Ainhoa, Medina-Luque, José, Díaz-Cabiale, Zaida, Craenenbroeck, Kathleen Van, Borroto-Escuela, Dasiel O, Kehr, Jan, Rodríguez de Fonseca, Fernando, Santín, Luis, de la Calle, Adelaida, Fuxe, Kjell
• Format: Journal Article
• Language: English
• Published: United States 01.09.2017
• Subjects: Analgesics, Opioid - pharmacology; Animals; Autoradiography; Benzamides - pharmacology; Caudate Nucleus - drug effects; Caudate Nucleus - metabolism; Dopamine Agonists - pharmacology; Drug Tolerance; Male; Morphine - pharmacology; Neostriatum - drug effects; Neostriatum - metabolism; Pars Compacta - drug effects; Pars Compacta - metabolism; Pars Reticulata - drug effects; Pars Reticulata - metabolism; Piperazines - pharmacology; Putamen - drug effects; Putamen - metabolism; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D4 - agonists; Receptors, Dopamine D4 - metabolism; Receptors, Opioid, mu - metabolism; Reward; Substance-Related Disorders - metabolism; Substantia Nigra - drug effects; Substantia Nigra - metabolism; caudate putamen; dopamine D4 receptor; morphine
• ISSN: 1355-6215; 1369-1600
• DOI: 10.1111/adb.12407

Morphine is one of the most effective drugs used for pain management, but it is also highly addictive. Morphine elicits acute and long-term adaptive changes at cellular and molecular level in the brain, which play a critical role in the development of tolerance, dependence and addiction. Previous studies indicated that the dopamine D receptor (D R) activation counteracts morphine-induced adaptive changes of the μ opioid receptor (MOR) signaling in the striosomes of the caudate putamen (CPu), as well as the induction of several Fos family transcription factors. Thus, it has been suggested that D R could play an important role avoiding some of the addictive effects of morphine. Here, using different drugs administration paradigms, it is determined that the D R agonist PD168,077 prevents morphine-induced activation of the nigrostriatal dopamine pathway and morphological changes of substantia nigra pars compacta (SNc) dopamine neurons, leading to a restoration of dopamine levels and metabolism in the CPu. Results from receptor autoradiography indicate that D R activation modulates MOR function in the substantia nigra pars reticulata (SNr) and the striosomes of the CPu, suggesting that these regions are critically involved in the modulation of SNc dopamine neuronal function through a functional D R/MOR interaction. In addition, D R activation counteracts the rewarding effects of morphine, as well as the development of hyperlocomotion and physical dependence without any effect on its analgesic properties. These results provide a novel role of D R agonist as a pharmacological strategy to prevent the adverse effects of morphine in the treatment of pain.